Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Vidarabine is an antiviral agent used to treat various viral infections. A nucleoside antibiotic isolated from Streptomyces antibioticus.
- Mechanism
- Curator reviewed
Vidarabine stops replication of herpes viral DNA in 2 ways: 1) competitive inhibition of viral DNA polymerase, and consequently 2) incorporation into and termination of the growing viral DNA chain. Vidarabine is sequentially phosphorylated by kinases to the triphosphate ara-ATP, which is the active form of vidarabine that acts as both an inhibitor and a substrate of viral DNA polymerase. By acting as a substrate for viral DNA polymerase, ara-ATP competitively inhibits dATP leading to the formation of ‘faulty’ DNA. Ara-ATP can also be incorporated into the DNA strand to replace many of the adenosine bases, resulting in the disruption of DNA synthesis.
- Primary indication
- For treatment of chickenpox - varicella, herpes zoster and herpes simplexCurator reviewed
- Formula / weight
- C10H13N5O4 · 267.2413 g/mol (avg)
- First approval
- United States, 1976
- Also known as
- Spongoadenosine
Resolves to
OIRDTQYFTABQOQ-UHTZMRCNSA-NSMILESNC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Vidarabine, and which of those have an active Phase 3 trial?